BCM
TVRD

Blume Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Blume Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-14
Closed -$7K – 242
2020
Q3 		$7K Hold
14
– – ﹤0.01% 184
2020
Q2 		$9K Hold
14
– – 0.01% 173
2020
Q1 		$6K Hold
14
– – ﹤0.01% 200
2019
Q4 		$8K Hold
14
– – ﹤0.01% 194
2019
Q3 		$9K Hold
14
– – ﹤0.01% 188
2019
Q2 		$11K Hold
14
– – 0.01% 174
2019
Q1 		$10K Buy
+14
New +$8.38K 0.01% 190

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Blume Capital Management's TVRD Position: Q4 2020 in Review

Blume Capital Management sold out of Tvardi Therapeutics (TVRD) in Q4 2020, closing a stake of 14 shares — an estimated $7K sold.

Blume Capital Management first reported a position in TVRD in Q1 2019 and held it in 7 quarters. The position peaked at $11K in Q2 2019. 155 funds tracked by Wall St. Rank hold TVRD as of Q4 2020.

  • Blume Capital Management reported no remaining Tvardi Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Blume Capital Management sold 14 Tvardi Therapeutics shares in Q4 2020, an estimated $7K.
  • Blume Capital Management first reported a position in Tvardi Therapeutics in Q1 2019 and held it in 7 quarters.
  • Blume Capital Management's Tvardi Therapeutics position peaked at $11K in Q2 2019.
  • 155 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2020.

Based on Blume Capital Management's 13F filing for Q4 2020, filed 9 Feb 2021.